Methylthioadenosine reprograms macrophage activation through adenosine receptor stimulation.

Area of Science:

• Immunology
• Pharmacology

Background:

• Inflammation resolution requires balancing pathogen clearance and tissue damage.
• Macrophages play a key role in switching from pro-inflammatory to anti-inflammatory states.
• Targeting macrophage responses is a strategy for therapeutic intervention.

Purpose of the Study:

• To investigate the anti-inflammatory effects of methylthioadenosine (MTA).
• To elucidate the mechanism by which MTA regulates inflammatory pathways in macrophages.
• To determine MTA's potential as a therapeutic agent for inflammation resolution.

Main Methods:

• Stimulation of macrophages with various Toll-like receptor (TLR) ligands.
• Assessment of tumor necrosis factor-alpha (TNFα) production.
• Analysis of cell surface marker expression (CD69, CD86) and NF-κB signaling.
• Investigation of MTA's mechanism via adenosine A2 receptor signaling.
• Evaluation of lipopolysaccharide (LPS) tolerance and IL-1β production.

Main Results:

• MTA inhibited TNFα production induced by multiple TLR ligands.
• MTA reduced the surface expression of CD69 and CD86, and decreased NF-κB signaling.
• The anti-inflammatory effects of MTA were mediated through adenosine A2 receptor activation.
• MTA enhanced LPS tolerance, indicating a shift towards an anti-inflammatory phenotype.
• MTA did not affect interleukin-1 beta (IL-1β) production or processing.

Conclusions:

• MTA effectively suppresses pro-inflammatory responses in macrophages.
• MTA reprograms TLR activation pathways through adenosine A2 receptors to promote inflammation resolution.
• MTA demonstrates therapeutic potential for managing inflammatory conditions.